- Nvidia is giving its newest AI chips to small cloud providers that compete with major players like Amazon Web Services and Google.
- The company is also asking these small cloud providers for the names of their customers, allowing Nvidia to potentially favor certain AI startups.
- This move highlights Nvidia's dominance as a major supplier of graphics processing units (GPUs) for AI, which are currently in high demand.
- The scarcity of GPUs has led to increased competition among cloud providers and Nvidia's actions could further solidify its position in the market.
- This move by Nvidia raises questions about fairness and competition in the AI industry.
Salesforce introduced its AI layer, Einstein, in 2016. Recently, it announced the release of Einstein Studio, allowing customers to bring their own model into Data Cloud. This solution is aimed at companies with sophisticated data teams who want to put their existing models to work in other contexts. Salesforce is also working on partnerships with other platforms like Google Vertex AI and plans to support Databricks and Snowflake in the future. This move suggests that Salesforce is positioning itself as a data company.
Google has invested billions of dollars in various healthcare initiatives to tackle the challenges in the industry and improve healthcare through innovations such as Care Studio and Healthcare Data Engine, with a focus on addressing the needs of patients, providers, and enterprises.
Precious, a cloud platform developed by the University of Ioannina, uses cutting-edge machine learning technology to store and analyze medical data, offering a range of applications in the field of precision medicine and benefiting both scientific advancement and patient wellbeing.
Google is aiming to increase its market share in the cloud industry by developing AI tools to compete with Microsoft and Amazon.
General Motors is collaborating with Google to introduce AI technologies throughout its business, including a partnership on GM's OnStar Interactive Virtual Assistant and exploring the potential applications of artificial intelligence in the automotive industry.
Ginkgo Bioworks and Google Cloud have entered into a five-year strategic partnership to develop and deploy AI tools for biology and biosecurity, with Ginkgo making Google its primary cloud services provider and receiving funding for the development of foundation models and applications.
Artificial intelligence (AI) has the potential to greatly improve health care globally by expanding access to health services, according to Google's chief health officer, Karen DeSalvo. Through initiatives such as using AI to monitor search queries for potential self-harm, as well as developing low-cost ultrasound devices and automated screening for tuberculosis, AI can address health-care access gaps and improve patient outcomes.
Google Cloud has launched the fifth generation of its tensor processing units (TPUs), offering improved efficiency and cost-effectiveness for AI training and inferencing.
Google is expanding access to its large language models, including its healthcare-specific model called Med-PaLM 2, in order to compete with Amazon and Microsoft in the healthcare sector, but challenges remain for the widespread use of AI in medicine.
Nvidia and Google Cloud Platform are expanding their partnership to support the growth of AI and large language models, with Google now utilizing Nvidia's graphics processing units and gaining access to Nvidia's next-generation AI supercomputer.
Google Cloud is heavily investing in generative AI, leveraging its innovations in Tensor Processing Units (TPUs) to provide accelerated computing for training and inference. They offer a wide range of foundation models, including PaLM, Imagen, Codey, and Chirp, allowing for customization and use in specific industries. Google Cloud's Vertex AI platform, combined with no-code tools, enables researchers, developers, and practitioners to easily work with generative AI models. Additionally, Google has integrated their AI assistant, Duet AI, with various cloud services to automate tasks and assist developers, operators, and security professionals.
An AI-generated COVID drug enters clinical trials, GM and Google strengthen their AI partnership, and Israel unveils an advanced AI-powered surveillance plane, among other AI technology advancements.
Google Cloud's CEO, Thomas Kurian, stated that the company's latest AI products, Duet AI in Workspace and Vertex AI, have the potential to revolutionize the market and bring AI capabilities to every department and industry, similar to how Google simplified access to the internet.
Healthcare revenue cycle management provider Aspirion has acquired Artificial Intelligence (AI) and machine learning firm Infinia ML to enhance operational effectiveness, recovery yield, and collections for its healthcare clients. Infinia ML will operate as Aspirion's research and development engine, focusing on AI capabilities to drive financial performance improvements for healthcare providers.
Google has provided a select group of companies with early access to its conversational AI software, Gemini, which aims to compete with OpenAI's GPT-4 model and will be available through its Google Cloud Vertex AI service.
Google's AI arm, DeepMind, has developed AlphaMissense, an AI tool that can predict the harmfulness of genetic mutations with 90% accuracy, potentially aiding in the research and treatment of rare diseases.
Google has announced that its AI tool, Bard, can now be linked to other Google products, allowing users to easily integrate the AI technology into various applications and services such as Gmail, Drive, YouTube, and Maps. Bard Extensions also offer features like summarizing emails, assisting with job searches, and verifying the accuracy of generated information.
Google Health's chief clinical officer, Michael Howell, discusses the advances in artificial intelligence (AI) that are transforming the field of medicine, emphasizing that AI should be seen as an assistive tool for healthcare professionals rather than a replacement for doctors. He highlights the significant improvements in AI models' ability to answer medical questions and provide patient care suggestions, but also acknowledges the challenges of avoiding AI gaslighting and hallucinations and protecting patient privacy and safety.
Major drugmakers are using artificial intelligence (AI) to accelerate drug development by quickly finding patients for clinical trials and reducing the number of participants needed, potentially saving millions of dollars. AI is increasingly playing a substantial role in human drug trials, with companies such as Amgen, Bayer, and Novartis using AI tools to scan vast amounts of medical data and identify suitable trial patients, significantly reducing the time and cost of recruitment. The use of AI in drug development is on the rise, with the US FDA receiving over 300 applications that incorporate AI or machine learning in drug development from 2016 through 2022.
